Cefpodoxime PCD Pharma Franchise Company

Cafoli Lifecare offers a Cefpodoxime range of 19 formulations across tablets, dry syrup and drops, manufactured in WHO-GMP certified facilities. Distributors building an oral-antibiotic portfolio can secure district-wise monopoly franchise rights across this widely prescribed cephalosporin with full promotional support.

What is Cefpodoxime?

Cefpodoxime proxetil is a third-generation oral cephalosporin antibiotic. It inhibits bacterial cell-wall synthesis and is active against many respiratory, urinary and skin pathogens, offering convenient twice-daily oral therapy including step-down after injectable antibiotics. Reference: PubChem - Cefpodoxime proxetil.

Available Forms

The Cafoli Cefpodoxime portfolio includes Tablets (plain and with clavulanic acid), paediatric Dry Syrup and Drops. Contact us for current pack presentations and combinations.

Therapeutic Applications

Cefpodoxime is prescribed for upper and lower respiratory tract infections, acute otitis media, sinusitis, urinary tract infections and skin infections in adults and children. Prescribers include physicians, paediatricians, ENT specialists, pulmonologists and general practitioners.

Why Cefpodoxime is a High-Potential Molecule for Distributors

Cefpodoxime is a favoured oral step-down cephalosporin and a common first-line choice in respiratory and paediatric practice, giving it consistent, year-round prescription volume. Its wide tablet, dry-syrup and drop range lets a distributor serve both adult and child patients, and cefpodoxime-clavulanate combinations add premium value to the line.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Cefpodoxime proxetil
2. MedlinePlus: Cefpodoxime
3. NCBI Bookshelf: Cephalosporins